Ensitrelvir Fumaric Acid: First Approval
YY Syed - Drugs, 2024 - Springer
Ensitrelvir fumaric acid (Xocova®) is an oral SARS-CoV-2 main protease inhibitor
developed by Shionogi for the treatment of SARS-CoV-2 infection. It is the first single-entity …
developed by Shionogi for the treatment of SARS-CoV-2 infection. It is the first single-entity …
A Phase 1 study of ensitrelvir fumaric acid tablets evaluating the safety, pharmacokinetics and food effect in healthy adult populations
R Shimizu, T Sonoyama, T Fukuhara, A Kuwata… - Clinical Drug …, 2023 - Springer
Background A reported clinical pharmacokinetics and safety study of suspension formulation
of ensitrelvir, a therapeutic agent used in severe acute respiratory syndrome coronavirus 2 …
of ensitrelvir, a therapeutic agent used in severe acute respiratory syndrome coronavirus 2 …
[HTML][HTML] Prophylactic effect of ensitrelvir in mice infected with SARS-CoV-2
H Nobori, K Baba, T Kuroda, K Baba, K Matsumoto… - Antiviral Research, 2024 - Elsevier
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the etiological cause of
coronavirus disease 2019 (COVID-19) and continues to be a major health concern …
coronavirus disease 2019 (COVID-19) and continues to be a major health concern …
Comprehensive Review on the Synthetic Strategies toward Anti-SARS-CoV-2 Drug Ensitrelvir
Y Liu, G Wu, Y Yang, W Hu, X Peng… - … Process Research & …, 2024 - ACS Publications
The outbreak and rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) have led to one of the most serious public health crises since the beginning of the …
CoV-2) have led to one of the most serious public health crises since the beginning of the …